Abstract
Liver stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for primary liver cancer and liver metastases. Liver SABR can provide high rates of local control however tumour doses are limited by dose to surrounding organs at risk including liver and gastrointestinal structures. Dose limits to liver are based on anatomical liver, without understanding of underlying liver function. This report describes a prospective clinical trial which measures the spatial variance of liver function through Tc-99m Mebrofenin SPECT in the context of liver SABR.
Highlights
There is an emerging body of evidence suggesting stereotactic ablative body radiotherapy (SABR) is an effective localised treatment modality for primary cancers of the liver and liver metastases
Liver SABR can provide high rates of local control tumour doses are limited by dose to surrounding organs at risk including liver and gastrointestinal structures
This report describes a prospective clinical trial which measures the spatial variance of liver function through Tc-99m Mebrofenin SPECT in the context of liver SABR
Summary
There is an emerging body of evidence suggesting stereotactic ablative body radiotherapy (SABR) is an effective localised treatment modality for primary cancers of the liver and liver metastases. Mean liver dose has been linked to liver function decline, as well as dose to 700 ml of liver [3]. These liver function dose-responses have been derived from anatomical liver [3]. Patients often have multiple co-morbidities that render sections of the liver non-functional, dose-response data is clouded by the fact that the radiotherapy dose may have been delivered to non-functional liver [3]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
